Clinical Trials Browser

Phase 1/2 × INDUSTRY × cirmtuzumab × Clear all

NCT03088878 2025-02-12

A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies

Phase 1/2 Completed

95 enrolled 25 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell